Tech Transfer Roundup: Erasca Calls On MD Anderson To Advance Its RAS/MAPK Pipeline

Precision oncology-focused Erasca, Inc. inked a research and development collaboration on 23 August with the University of Texas MD Anderson Cancer Center to evaluate multiple agents from Erasca’s pipeline targeting the RAS/MAPK pathway as either single-agent or combination therapies. Under the five-year agreement, the partners will conduct collaborative preclinical and clinical studies in non-small cell lung cancer (NSCLC), gastrointestinal malignancies and additional mutually agreed-upon indications.

Building upon existing research agreements, the alliance’s initial focus will be on Erasca’s ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601, which comprise the firm’s first MAPKlamp combination. (Also see "Erasca Unveils First Clinical Candidates, Aims To Create A MAPK Clamp" - Scrip, 6 January, 2021